A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Erasca, Inc.
Erasca, Inc.
Sapience Therapeutics
Linnaeus Therapeutics, Inc.
Provectus Pharmaceuticals
Merck Sharp & Dohme LLC
AbbVie
AbbVie
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Teva Branded Pharmaceutical Products R&D, Inc.
AstraZeneca
Merck Sharp & Dohme LLC
AstraZeneca
Genta Incorporated
Myrexis Inc.
SentoClone AB
Attenuon